Company Overview of Ardelyx, Inc.
Ardelyx, Inc. develops oral therapeutics to correct mineral metabolism and metabolic disorders. It offers RDX5791, a potent and selective inhibitor of NHE3, a sodium transporter on the surface of the intestinal epithelia; and RDX002, a minimally-systemic phosphate transport inhibitors targeting the intestinal phosphate transporter NaP2b for the treatment of phosphorus disorders associated with chronic kidney diseases and end-stage renal diseases. The company also provides RDX009, a non-systemic agent for treating type 2 diabetes that stimulate TGR5, a receptor found in the gastro-intestinal tract; and RDX013, a program that emphasizes non-systemic colonic potassium channel openers to increas...
34175 Ardenwood Boulevard
Fremont, CA 94555
Founded in 2007
Key Executives for Ardelyx, Inc.
Chairman and Chief Executive Officer
Vice President of Finance & Operations
Compensation as of Fiscal Year 2012.
Ardelyx, Inc. Key Developments
Ardelyx, Inc. Presents at Leerink Swann Global Healthcare Conference, Feb-14-2013 09:00 AM
Feb 7 13
Ardelyx, Inc. Presents at Leerink Swann Global Healthcare Conference, Feb-14-2013 09:00 AM. Venue: Waldorf Astoria Hotel, New York, New York, United States. Speakers: Michael G. Raab, Chairman and Chief Executive Officer.
Ardelyx, Inc. Presents at BIO-Europe 2012, Nov-12-2012
Nov 9 12
Ardelyx, Inc. Presents at BIO-Europe 2012, Nov-12-2012 . Venue: CCH Congress Center Hamburg, Am Dammtor / Marseiller Str, 20355 Hamburg, Germany.
AstraZeneca PLC and Ardelyx, Inc. Sign Licensing Agreement for NHE3 Inhibitor Programme
Oct 9 12
AstraZeneca PLC and Ardelyx, Inc. have signed a exclusive licensing agreement for Ardelyx's NHE3 inhibitor programme for the treatment of complications associated with end-stage renal disease (ESRD) and chronic kidney disease (CKD). The NHE3, the sodium-hydrogen antiporter 3, inhibitor programme includes the Phase 2-ready lead compound RDX5791. The partnership will focus on developing RDX5791 for use in ESRD and CKD in addition to irritable bowel syndrome and evaluating possible development in other diseases that are a consequence of sodium and fluid overload. AstraZeneca CVGI Innovative Medicines vice president and head Gunnar Olsson said the licensing agreement will enable the development of new medicines for people with renal complications, including those resulting from diabetes. With a novel mechanism of action, RDX5791 has the potential to have a major impact on how doctors treat these patients.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|